July 2013

Contents

Editorial

• Volume 14 Number 7/8 July/August 2013

Conference reports

• 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 30 June – 3 July 2013, Kuala Lumpur

• WHO 2013 guidelines: what about the missing formulations?

• WHO 2013 guidelines: when the risk:benefit may not favour starting at CD4 count of 500

• Efavirenz at 400 mg compared to standard 600 mg dose has similar efficacy with fewer side effects

• Dolutegravir update: drug resistance in people who are treatment-naive and -experienced

• Elvitegravir/cobicisat/tenofovir/FTC: Stribild studies at IAS 2013

• Non-standard combinations: NRTI-sparing combinations

• ARVs and bone health: the role of NRTIs in second-line therapy

• No viral load rebound off-ART following stem cell transplant: two “cure” cases using reduced intensity conditioning chemotherapy and CCR5 d-32 negative donors

• HIV cure research: further capsules at IAS 2013

• Partner-dependent immune differences may protect against HIV infection

• Pipeline oral HCV drugs and generic global access to DAAs: the need to mirror ARV programmes

• 5th International Workshop on HIV Pediatrics, 28-29 June 2013, Kuala Lumpur

• Vertical transmission continues to decline in UK and Ireland

• Decline in late preterm delivery with vaginal birth in Europe

• High loss to follow up among asymptomatic women starting ART in pregnancy in Option B+

• Decreased growth in ART exposed uninfected infants in Botswana

• Antiretrovirals, doses and formulations for children

• International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, 4-8 June 2013, Toronto

• Higher intracellular concentrations with tenofovir alafenamide (TAF) overcomes K65R and other key NRTI resistance in vitro

• Tentative phenotypic cut offs for dolutegravir: guidance for use with integrase resistance

• S/GSK744 and long-acting formulation indicate broadly similar resistance profile to dolutegravir

• One in five people with recent HIV infection in Spain have X4/R5 mixed tropic virus

Antiretrovirals

• Community request Gilead to study and develop separate formulation of new tenofovir prodrug

Treatment access

• Ending global use of d4T: UNITAID to tip market to safer alternatives

• TRIPS extension for least developed countries

HIV prevention and transmission

• Bangkok Tenofovir Study: US CDC recommends oral PrEP for injecting drug users – based on 16 fewer infections over 5 years

Basic science and immunology

• Sad news regarding attempt to duplicate the cure achieved in Timothy Brown

• ART reduces HIV reservoirs in elite controllers: implications for cure research

Other news

• CROI website: vital community and research resource vanishes

• FDA guidance for industry HIV development and trials

On the web

• TAG report: Immune system, HIV, and ageing

• RITA! summer issue: HIV and cardiovascular disease

PDFs

• Volume 14 Number 7/8 July/August 2013 PDF